Faculty Profile

Passeri, Michlene,MD
Passeri, Michlene, MD

Assistant Professor

Chief, Neuroimmunology Division

Department: Neurology

Bio ,  Curriculum Vitae
 UTMB Health Profile
 UTMB Research Experts

  • Dr. Passeri is from Houston, Texas and attended medical school at Texas A&M Health Sciences center. She subsequently completed her residency training at the Barrow Neurological Institute in Phoenix, Arizona. During her fourth year in residency, she served as Chief Resident.

    She then completed a fellowship in Multiple Sclerosis and Neuroimmunology at the University of Colorado in 2022. She subsequently worked as a Neurologist in Laredo, TX in a medically underserved community for two years until she then joined UTMB faculty in September 2024.

    Dr. Passeri is an Assistant Professor of Neurology at UTMB and serves as a specialist in Multiple Sclerosis and Neuroimmunology where her clinical interests lie.
  • Medical/Professional School:

    MD, Texas A & M University System, Hsc, College of Medicine - Bryan, TX, 2017

    Internships:

    Internal Medicine, Creighton University Affiliated Hospital, St. Joseph's Hospital - Phoenix, AZ, 2018

    Residencies:

    Neurology, Barrow Neurological Institute - Phoenix, AZ, 2021

    Fellowships:

    Neuroimmunology, University of Colorado - Aurora, CO, 2022

    Certifications:

    Psychiatry & Neurology, American Board of Psychiatry & Neurology
    • Q.F.B. Chemistry and Pharmacobiology, Faculty of Chemical Sciences. Benemérita Universidad Autónoma de Puebla, Puebla, Mexico

    • Ph.D. Neurobiology, Faculty of Biological Sciences, Universidad Nacional Autónoma de Mexico, CDMX, Mexico

    • Postdoctoral Fellow, ORISE. Division of Neurotoxicology, Laboratory of Neurochemistry, National Center for Toxicological Research, Food and Drug Administration, USA
    • Sex differences in neurodegenerative diseases, mainly in AD

    • Role of the blood-brain barrier in AD

    • Neurotoxicity in Neurodegenerative Diseases

    • Neuroinflammation in Neurodegenerative Diseases
    • Perez-Severiano F, Salvatierra-Sanchez R, Rodriguez-Perez M, Cuevas-Martinez EY, Guevara J, Limon D, Maldonado PD, Medina-Campos ON, Pedraza-Chaverri J, Santamaria A (2004) S-Allylcysteine prevents amyloid-beta peptide-induced oxidative stress in rat hippocampus and ameliorates learning deficits. Eur J Pharmacol 489, 197-202.

    • Cuevas E, Limon D, Perez-Severiano F, Diaz A, Ortega L, Zenteno E, Guevara J (2009) Antioxidant effects of epicatechin on the hippocampal toxicity caused by amyloid-beta 25-35 in rats. Eur J Pharmacol 616, 122-127.

    • Cuevas E, Lantz SM, Tobon-Velasco JC, Newport GD, Wu Q, Virmani A, Ali SF, Santamaria A (2011) On the in vivo early toxic properties of A-beta 25-35 peptide in the rat hippocampus: involvement of the Receptor-for-Advanced Glycation-End-Products and changes in gene expression. Neurotoxicol Teratol 33, 288-296.

    • Cuevas E, Rosas-Hernandez H, Burks SM, Ramirez-Lee MA, Guzman A, Imam SZ, Ali SF, Sarkar S (2019) Amyloid Beta 25-35 induces blood-brain barrier disruption in vitro. Metab Brain Dis 34, 1365-1374.

    • Gu Q, Cuevas E, Raymick J, Kanungo J, Sarkar S (2020) Downregulation of 14-3-3 Proteins in Alzheimer's Disease. Mol Neurobiol 57, 32-40.

    • Sarkar S, Raymick J, Cuevas E, Rosas-Hernandez H, Hanig J (2020) Modification of methods to use Congo-red stain to simultaneously visualize amyloid plaques and tangles in human and rodent brain tissue sections. Metab Brain Dis 35, 1371-1383.

    • Rosas-Hernandez H, Cuevas E, Raymick JB, Robinson BL, Sarkar S (2020) Impaired Amyloid Beta Clearance and Brain Microvascular Dysfunction are Present in the Tg-SwDI Mouse Model of Alzheimer's Disease. Neuroscience 440, 48-55.

    • Apatiga-Perez R, Soto-Rojas LO, Campa-Cordoba BB, Luna-Viramontes NI, Cuevas E, Villanueva-Fierro I, Ontiveros-Torres MA, Bravo-Munoz M, Flores-Rodriguez P, Garces-Ramirez L, de la Cruz F, Montiel-Sosa JF, Pacheco-Herrero M, Luna-Munoz J (2021) Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer's disease. Metab Brain Dis.
  • 2020NCTR Special act award
    2019NCTR Special act award
    2018Member of the Mexican SNI, Level 1, by CONACyT, Mexico
    2017 - 2018President of the Arkansas Chapter of the Society for Neuroscience
    2014Travel award to Workshop Collaborative zebrafish model
    2014Quality of Life Award, NCTR
    2008First Place in "Science Fair", as a PI, UNAM
  • 2020 - PresentInternational Society to Advance Alzheimer's Research and Treatment
    2010 - PresentArkansas Chapter of the Society for Neuroscience
    2002 - PresentSociety for Neuroscience